PolarityTE™, Inc., (NASDAQ: COOL) today announced it has appointed Jon Mogford, PhD to the Board of Directors. Dr. Mogford has extensive experience in regenerative medicine and wound healing, with a long track record of leading large research institutions. He currently oversees research strategy as Vice Chancellor for Research across the entire Texas A&M University System, and led significant expansion and collaborations while serving as Deputy Director of the Defense Sciences Office (DSO) within the Defense Advanced Research Projects Agency (DARPA) in the U.S. Department of Defense.
"We are excited to announce Dr. Jon Mogford as a new member of the PolarityTE™ Board of Directors. Dr. Mogford's DARPA led programs in wound healing, hemostatic biomaterials, and bioreactor production of universal donor red blood cells provide critical insight to the PolarityTE™ team. In addition, Dr. Mogford spearheaded a joint collaboration between DARPA, the FDA, and the NIH, which speaks volumes to his abilities to create strategic partnerships and work with the government agencies. The appointment of Dr. Mogford is an instrumental step toward achieving our goals, and adds a uniquely new pillar to our team," said Denver Lough, MD, PhD, Chairman and CEO.
Newly appointed board member, Jon Mogford, PhD, remarked, "I am thrilled to join the Polarity team and its Board of Directors. Polarity's regenerative platform takes a remarkably new approach to tissue engineering, and changes the very principles that built the field. There are a significant number of patients that can benefit from this technology, and I include wounded warriors and veterans high on that list. Given this opportunity to join the Polarity team, I will utilize my background to help translate and commercially scale the products being developed by Polarity, for both the civilian and military world."
During December 2016 PolarityTE™ entered into an Agreement and Plan of Reorganization to acquire certain intellectual property rights developed by Dr. Lough. Completion of the acquisition is subject to a number of conditions, including stockholder approval. There can be no assurance that the conditions will be met or that the acquisition will be successful. The acquisition, and our business generally, is subject to a number of risks that are more fully described under "Risk Factors" that appear in our filings and reports with the SEC.
About Jon Mogford, PhD
Dr. Mogford serves as the Vice Chancellor for Research for The Texas A&M University System and provides research and development leadership to the System's eleven universities and seven state agencies encompassing 30,000 faculty and staff, 135,000 students, a budget of more than $4 billion and research expenditures of more than $945 million annually. As the leader of the A&M System Office of Research, Dr. Mogford develops strategic partnerships with external agencies, foundations, academic institutions, and commercial corporations to enhance the system's mission of research, teaching, service, and economic development for the state of Texas.
